Endocrine Abstracts

Background: Men who receive gonadotoxic treatment for cancer may be at risk of hypogonadism. The extent of this risk is unknown. Severe hypogonadism is associated with fatigue, sexual dysfunction, reduced muscle mass and obesity. Diagnosing mild or moderate hypogonadism is difficult and requires evaluation.Aim: The aim of this study was to identify hypogonadism in young male survivors of cancer.Subjects and Methods: The study was a...